Lucid Capital analyst Elemer Piros initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $8 price target The company is developing chronic steroid treatments for rare diseases with “blockbuster potential,” the analyst tells investors in a research note. The firm believes the company’s EryDex is set to become a blockbuster treatment in the lead ataxia-telangiectasia indication alone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX: